Funding profile · Regenerative medicine

dNovo

One announced seed round, no SEC Form D filed under the company’s name, and a founder who has since started a different company. Here is what the record shows and does not show.

$2.7MSeed round, company reported (Jan 24, 2022)
$0Form D filings found under dNovo Inc on SEC EDGAR
15Investors named in the seed announcement
4 yrsGap between the 2018 Y Combinator batch and the 2022 funding announcement

Data as of September 25, 2026. Company reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2018 Y Combinator batch Not disclosed Y Combinator Directory
Jan 24, 2022 Seed $2.7M announced Y Combinator, Felicis Ventures, Soma Capital, Yintai Investment Company LLC, Ataria Ventures, Duro Ventures, Pioneer Fund, and 8 named individuals including Paul Buchheit and Joey Krug Company release
2022 to 2026 No further round announced Not disclosed None found Gap

What the filings show

There is nothing to show. Searching SEC EDGAR’s company database and its full text search system for dNovo Inc, dNovo, and dNovobio turns up no Form D notice filed under any of those names. A search that surfaced other biotech Form D filings from around the same period, including one from an unrelated company called Myodenovo Inc, returned no match for dNovo. That does not by itself mean no filing exists; a company can raise money under Section 4(a)(2) of the Securities Act instead of Regulation D and never file a Form D at all. But it does mean the only number on the table for this raise is the one the company put out itself.

Reading the record

  1. No Form D means no federal cross check.Every number below the $2.7 million headline, meaning any closing date, any per investor amount, or any confirmation the round actually closed, comes only from the company’s own January 2022 release and outlets that repeated it.
  2. The figure has held steady across sources that used it.BioSpace, New Atlas, FirstWord Pharma and the research aggregator Tracxn all cite the same $2.7 million seed figure from the same January 24, 2022 release. No outlet found in this research reported a different number for that round.
  3. Fifteen named backers, no dollar figure attached to any one of them.The release names Y Combinator, Felicis Ventures, Soma Capital and Yintai Investment Company LLC, plus three smaller funds (Ataria Ventures, Duro Ventures, Pioneer Fund) and eight individuals, including early Gmail engineer Paul Buchheit and Luno co-founder Joey Krug. Unlike a Form D, the release gives no breakdown of how much came from each.
  4. A second, higher figure appears in at least one database, unconfirmed elsewhere.Startup Intros, a third party company database, lists dNovo’s total raised as $3.0 million in a single seed round dated January 2022, and pairs it with an investor list that includes large funds such as Tiger Global Management, SoftBank and General Catalyst, none of which appear in dNovo’s own release or in any news outlet’s coverage of it. No independent source found in this research corroborates that larger figure or that investor list.
  5. Silence since 2022.dNovo finished its Y Combinator batch in 2018 and made no public funding announcement until January 2022. Nothing has been announced since. A hair loss industry pipeline tracker, last updated in November 2024, records the 2022 announcement and nothing after it.
  6. The founder’s capital has moved elsewhere.Ernesto Lujan is now chief scientific officer and a co-founder of Kangaroo Biomedical, a separate San Francisco company working on artificial placenta and artificial womb technology, which has itself raised $4.5 million in seed funding from investors including Draper Associates. That money went to Kangaroo Biomedical, not to dNovo, and the two companies’ fundraising should not be confused.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k), PMA filing, or registered clinical trial found for dNovo. Gap
Preclinical data Company reports its reprogrammed human hair stem cells produced hair on mice, shown in a photograph released with the January 2022 funding news. No peer reviewed paper on the hair application was found. Company stated
Patent Described as patent pending by the company and by Y Combinator’s listing. No granted US patent for a hair application under dNovo or Ernesto Lujan was identified. Gap
Status Y Combinator’s company page lists dNovo as inactive. Founder Ernesto Lujan’s LinkedIn profile lists his current role at Kangaroo Biomedical, not dNovo. Independent
Founder’s next venture Kangaroo Biomedical, co-founded by Lujan in 2023 with CEO Landice Gao, has raised $4.5M in seed funding including from Draper Associates, separate from any dNovo raise. Independent

What to watch

  • Whether a Form D or any SEC filing ever appears under dNovo Inc’s name.
  • Whether dNovo’s patent application, if one exists, ever publishes or is reassigned.
  • Whether Kangaroo Biomedical, Ernesto Lujan’s current company, absorbs any of dNovo’s technology, patents or remaining team.
  • Whether a still-active competitor in reprogrammed hair therapy, such as Stemson Therapeutics or Pelage Pharmaceuticals, files anything that references dNovo’s patent applications.

The dNovo story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Loop Health: Shared investor: General Catalyst. A Pune company that sells group health insurance as a licensed broker and employs its own doctors to deliver the everyday care those policies do not cover
  • Medinas Health: Shared investor: General Catalyst. A cloud based marketplace and software platform that helped hospitals value, redeploy and resell their surplus medical equipment
  • Pharos: Shared investor: Felicis. An AI system that reads hospital charts and produces the quality measures nurses now extract by hand
  • Carrot Fertility: Shared investor: Precursor. A benefits platform that sits beside an employer health plan and pays for fertility and family building care

Sources

  1. Public recordSEC EDGAR company and full text search, dNovo, dNovo Inc, dNovobio, no Form D foundSEC EDGAR · searched Sep 25, 2026
  2. CompanydNovo Emerges From Stealth With Its Potential Cure for Hair LossBusiness Wire · Jan 24, 2022
  3. IndependentdNovo Emerges From Stealth With Its Potential Cure for Hair LossBioSpace, Tristan Manalac · Jan 24, 2022
  4. IndependentdNovo’s novel baldness treatment takes a direct route to hair regrowthNew Atlas, Nick Lavars · Feb 7, 2022
  5. IndependentdNovo company profile and funding summaryTracxn · accessed Jun 2023 snapshot
  6. AggregatordNovo Bio: Funding, Team and InvestorsStartup Intros · accessed Jul 2026 snapshot
  7. IndependentdNovo: De Novo Hair Regeneration, including status updateHair Loss Cure 2020 · Jan 20, 2022, checked Sep 2026
  8. IndependentKangaroo Biomedical Wants to Build an Artificial Womb for HumansGlitchwire, Science Desk · Jun 19, 2026
  9. IndependentAndrogenetic Alopecia Therapies Master List, dNovo entryFollicle Thought · updated through Nov 2024

Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. No Form D was found for this company. Healthcare Venture Capital Fund holds no position in dNovo. This page is not an offer to sell or a recommendation to buy any security.